#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1.
1-1	0-2	1.	_	_	_	_

#Text=Introduction
2-1	3-15	Introduction	abstract	new	_	_

#Text=Cancer is a major cause of human death worldwide .
3-1	16-22	Cancer	abstract	new	coref	3-3[3_0]
3-2	23-25	is	_	_	_	_
3-3	26-27	a	abstract[3]	giv[3]	coref	5-5[0_3]
3-4	28-33	major	abstract[3]	giv[3]	_	_
3-5	34-39	cause	abstract[3]	giv[3]	_	_
3-6	40-42	of	abstract[3]	giv[3]	_	_
3-7	43-48	human	abstract[3]|event[4]	giv[3]|new[4]	_	_
3-8	49-54	death	abstract[3]|event[4]	giv[3]|new[4]	_	_
3-9	55-64	worldwide	abstract[3]	giv[3]	_	_
3-10	65-66	.	_	_	_	_

#Text=Most cancer patients receive chemotherapy and radiation therapy , they are often only partially effective and lead to a variety of serious side effects .
4-1	67-71	Most	person[5]	new[5]	ana	4-10[0_5]
4-2	72-78	cancer	person[5]	new[5]	_	_
4-3	79-87	patients	person[5]	new[5]	_	_
4-4	88-95	receive	_	_	_	_
4-5	96-108	chemotherapy	abstract	new	coref	6-3
4-6	109-112	and	_	_	_	_
4-7	113-122	radiation	abstract|abstract[8]	new|new[8]	coref|coref	6-5|6-5[20_8]
4-8	123-130	therapy	abstract[8]	new[8]	_	_
4-9	131-132	,	_	_	_	_
4-10	133-137	they	person	giv	coref	5-12[15_0]
4-11	138-141	are	_	_	_	_
4-12	142-147	often	_	_	_	_
4-13	148-152	only	_	_	_	_
4-14	153-162	partially	_	_	_	_
4-15	163-172	effective	_	_	_	_
4-16	173-176	and	_	_	_	_
4-17	177-181	lead	_	_	_	_
4-18	182-184	to	_	_	_	_
4-19	185-186	a	abstract[10]	new[10]	_	_
4-20	187-194	variety	abstract[10]	new[10]	_	_
4-21	195-197	of	abstract[10]	new[10]	_	_
4-22	198-205	serious	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-23	206-210	side	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-24	211-218	effects	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-25	219-220	.	_	_	_	_

#Text=In recent decades , cancer immunotherapy has been validated as stimulating patients ’ own immune systems to eliminate cancers .
5-1	221-223	In	_	_	_	_
5-2	224-230	recent	time[12]	new[12]	_	_
5-3	231-238	decades	time[12]	new[12]	_	_
5-4	239-240	,	_	_	_	_
5-5	241-247	cancer	abstract|abstract[14]	giv|new[14]	coref|coref	6-8|6-8[22_14]
5-6	248-261	immunotherapy	abstract[14]	new[14]	_	_
5-7	262-265	has	_	_	_	_
5-8	266-270	been	_	_	_	_
5-9	271-280	validated	_	_	_	_
5-10	281-283	as	_	_	_	_
5-11	284-295	stimulating	_	_	_	_
5-12	296-304	patients	person[15]|abstract[16]	giv[15]|new[16]	_	_
5-13	305-306	’	person[15]|abstract[16]	giv[15]|new[16]	_	_
5-14	307-310	own	abstract[16]	new[16]	_	_
5-15	311-317	immune	abstract[16]	new[16]	_	_
5-16	318-325	systems	abstract[16]	new[16]	_	_
5-17	326-328	to	_	_	_	_
5-18	329-338	eliminate	_	_	_	_
5-19	339-346	cancers	abstract	new	_	_
5-20	347-348	.	_	_	_	_

#Text=Compared to chemotherapy and radiation therapy , cancer immunotherapy can specifically target tumor cells by modulating immune cells without damage to normal cells .
6-1	349-357	Compared	_	_	_	_
6-2	358-360	to	_	_	_	_
6-3	361-373	chemotherapy	abstract	giv	_	_
6-4	374-377	and	_	_	_	_
6-5	378-387	radiation	abstract|abstract[20]	giv|giv[20]	coref	15-10[98_20]
6-6	388-395	therapy	abstract[20]	giv[20]	_	_
6-7	396-397	,	_	_	_	_
6-8	398-404	cancer	abstract|abstract[22]	giv|giv[22]	coref	7-4
6-9	405-418	immunotherapy	abstract[22]	giv[22]	_	_
6-10	419-422	can	_	_	_	_
6-11	423-435	specifically	_	_	_	_
6-12	436-442	target	_	_	_	_
6-13	443-448	tumor	abstract|place[24]	new|new[24]	coref	6-17[25_24]
6-14	449-454	cells	place[24]	new[24]	_	_
6-15	455-457	by	_	_	_	_
6-16	458-468	modulating	_	_	_	_
6-17	469-475	immune	place[25]	giv[25]	coref	6-22[27_25]
6-18	476-481	cells	place[25]	giv[25]	_	_
6-19	482-489	without	_	_	_	_
6-20	490-496	damage	abstract[26]	new[26]	_	_
6-21	497-499	to	abstract[26]	new[26]	_	_
6-22	500-506	normal	abstract[26]|place[27]	new[26]|giv[27]	coref	8-10[49_27]
6-23	507-512	cells	abstract[26]|place[27]	new[26]|giv[27]	_	_
6-24	513-514	.	_	_	_	_

#Text=A variety of cancer immunotherapies , including DC-based cancer vaccines , chimeric antigen receptor-T lymphocyte therapies , immune checkpoint blockade antibody therapies , oncolytic vaccine , and cytokines therapies , have been developed to induce tumor-specific and cytotoxic T lymphocyte immune responses .
7-1	515-516	A	abstract[28]	new[28]	_	_
7-2	517-524	variety	abstract[28]	new[28]	_	_
7-3	525-527	of	abstract[28]	new[28]	_	_
7-4	528-534	cancer	abstract[28]|abstract|abstract[30]	new[28]|giv|new[30]	coref	7-9
7-5	535-550	immunotherapies	abstract[28]|abstract[30]	new[28]|new[30]	_	_
7-6	551-552	,	abstract[28]|abstract[30]	new[28]|new[30]	_	_
7-7	553-562	including	abstract[28]|abstract[30]	new[28]|new[30]	_	_
7-8	563-571	DC-based	abstract[28]|abstract[30]|object[32]	new[28]|new[30]|new[32]	_	_
7-9	572-578	cancer	abstract[28]|abstract[30]|abstract|object[32]	new[28]|new[30]|giv|new[32]	coref	14-14
7-10	579-587	vaccines	abstract[28]|abstract[30]|object[32]	new[28]|new[30]|new[32]	_	_
7-11	588-589	,	abstract[28]|abstract[30]	new[28]|new[30]	_	_
7-12	590-598	chimeric	abstract[28]|abstract[30]|abstract[36]	new[28]|new[30]|new[36]	_	_
7-13	599-606	antigen	abstract[28]|abstract[30]|substance|abstract[36]	new[28]|new[30]|new|new[36]	coref	13-7[81_0]
7-14	607-617	receptor-T	abstract[28]|abstract[30]|abstract|abstract[36]	new[28]|new[30]|new|new[36]	_	_
7-15	618-628	lymphocyte	abstract[28]|abstract[30]|abstract|abstract[36]	new[28]|new[30]|new|new[36]	coref	7-39[45_0]
7-16	629-638	therapies	abstract[28]|abstract[30]|abstract[36]	new[28]|new[30]|new[36]	_	_
7-17	639-640	,	abstract[28]|abstract[30]	new[28]|new[30]	_	_
7-18	641-647	immune	abstract[28]|abstract[30]|abstract[38]|abstract[40]	new[28]|new[30]|new[38]|new[40]	_	_
7-19	648-658	checkpoint	abstract[28]|abstract[30]|place|abstract[38]|abstract[40]	new[28]|new[30]|new|new[38]|new[40]	_	_
7-20	659-667	blockade	abstract[28]|abstract[30]|abstract[38]|abstract[40]	new[28]|new[30]|new[38]|new[40]	_	_
7-21	668-676	antibody	abstract[28]|abstract[30]|substance|abstract[40]	new[28]|new[30]|new|new[40]	_	_
7-22	677-686	therapies	abstract[28]|abstract[30]|abstract[40]	new[28]|new[30]|new[40]	_	_
7-23	687-688	,	abstract[28]|abstract[30]	new[28]|new[30]	_	_
7-24	689-698	oncolytic	abstract[28]|abstract[30]|substance[41]	new[28]|new[30]|new[41]	coref	12-1[76_41]
7-25	699-706	vaccine	abstract[28]|abstract[30]|substance[41]	new[28]|new[30]|new[41]	_	_
7-26	707-708	,	abstract[28]|abstract[30]	new[28]|new[30]	_	_
7-27	709-712	and	abstract[28]|abstract[30]	new[28]|new[30]	_	_
7-28	713-722	cytokines	abstract[28]|abstract[30]|abstract|abstract[43]	new[28]|new[30]|new|new[43]	coref|coref	8-1[48_43]|11-13[72_0]
7-29	723-732	therapies	abstract[28]|abstract[30]|abstract[43]	new[28]|new[30]|new[43]	_	_
7-30	733-734	,	_	_	_	_
7-31	735-739	have	_	_	_	_
7-32	740-744	been	_	_	_	_
7-33	745-754	developed	_	_	_	_
7-34	755-757	to	_	_	_	_
7-35	758-764	induce	_	_	_	_
7-36	765-779	tumor-specific	abstract[46]	new[46]	coref	9-23[59_46]
7-37	780-783	and	abstract[46]	new[46]	_	_
7-38	784-793	cytotoxic	abstract[46]	new[46]	_	_
7-39	794-795	T	person|abstract[45]|abstract[46]	new|giv[45]|new[46]	coref	9-18
7-40	796-806	lymphocyte	abstract[45]|abstract[46]	giv[45]|new[46]	_	_
7-41	807-813	immune	abstract[46]	new[46]	_	_
7-42	814-823	responses	abstract[46]	new[46]	_	_
7-43	824-825	.	_	_	_	_

#Text=Dendritic cell based therapies have been widely investigated because dendritic cells ( DCs ) are thought to be the initiator in modulating immunity .
8-1	826-835	Dendritic	object[47]|abstract[48]	new[47]|giv[48]	ana|coref	9-16[0_48]|27-8[203_47]
8-2	836-840	cell	object[47]|abstract[48]	new[47]|giv[48]	_	_
8-3	841-846	based	abstract[48]	giv[48]	_	_
8-4	847-856	therapies	abstract[48]	giv[48]	_	_
8-5	857-861	have	_	_	_	_
8-6	862-866	been	_	_	_	_
8-7	867-873	widely	_	_	_	_
8-8	874-886	investigated	_	_	_	_
8-9	887-894	because	_	_	_	_
8-10	895-904	dendritic	place[49]	giv[49]	coref	9-5[54_49]
8-11	905-910	cells	place[49]	giv[49]	_	_
8-12	911-912	(	_	_	_	_
8-13	913-916	DCs	place	new	coref	9-1
8-14	917-918	)	_	_	_	_
8-15	919-922	are	_	_	_	_
8-16	923-930	thought	_	_	_	_
8-17	931-933	to	_	_	_	_
8-18	934-936	be	_	_	_	_
8-19	937-940	the	abstract[51]	new[51]	_	_
8-20	941-950	initiator	abstract[51]	new[51]	_	_
8-21	951-953	in	abstract[51]	new[51]	_	_
8-22	954-964	modulating	abstract[51]	new[51]	_	_
8-23	965-973	immunity	abstract[51]|abstract	new[51]|new	coref	18-32[121_0]
8-24	974-975	.	_	_	_	_

#Text=DCs are known as professional antigen-presenting cells , responsible for swallowing tumor-associated antigens , presenting them to T lymphocytes , and inducing antigen-specific immune responses .
9-1	976-979	DCs	place	giv	coref	10-2
9-2	980-983	are	_	_	_	_
9-3	984-989	known	_	_	_	_
9-4	990-992	as	_	_	_	_
9-5	993-1005	professional	place[54]	giv[54]	coref	14-14[92_54]
9-6	1006-1024	antigen-presenting	place[54]	giv[54]	_	_
9-7	1025-1030	cells	place[54]	giv[54]	_	_
9-8	1031-1032	,	place[54]	giv[54]	_	_
9-9	1033-1044	responsible	place[54]	giv[54]	_	_
9-10	1045-1048	for	_	_	_	_
9-11	1049-1059	swallowing	_	_	_	_
9-12	1060-1076	tumor-associated	substance[55]	new[55]	coref	10-11[62_55]
9-13	1077-1085	antigens	substance[55]	new[55]	_	_
9-14	1086-1087	,	_	_	_	_
9-15	1088-1098	presenting	_	_	_	_
9-16	1099-1103	them	abstract	giv	_	_
9-17	1104-1106	to	_	_	_	_
9-18	1107-1108	T	person|substance[58]	giv|new[58]	coref|coref	13-31|13-31[87_58]
9-19	1109-1120	lymphocytes	substance[58]	new[58]	_	_
9-20	1121-1122	,	_	_	_	_
9-21	1123-1126	and	_	_	_	_
9-22	1127-1135	inducing	_	_	_	_
9-23	1136-1152	antigen-specific	abstract[59]	giv[59]	coref	11-23[75_59]
9-24	1153-1159	immune	abstract[59]	giv[59]	_	_
9-25	1160-1169	responses	abstract[59]	giv[59]	_	_
9-26	1170-1171	.	_	_	_	_

#Text=When DCs mature and become activated , they will swallow the foreign substances and subsequently present the antigenic epitopes on major histocompatibility complex ( MHC ) molecules .
10-1	1172-1176	When	_	_	_	_
10-2	1177-1180	DCs	place	giv	ana	10-8
10-3	1181-1187	mature	_	_	_	_
10-4	1188-1191	and	_	_	_	_
10-5	1192-1198	become	_	_	_	_
10-6	1199-1208	activated	_	_	_	_
10-7	1209-1210	,	_	_	_	_
10-8	1211-1215	they	place	giv	coref	11-6
10-9	1216-1220	will	_	_	_	_
10-10	1221-1228	swallow	_	_	_	_
10-11	1229-1232	the	substance[62]	giv[62]	coref	19-23[130_62]
10-12	1233-1240	foreign	substance[62]	giv[62]	_	_
10-13	1241-1251	substances	substance[62]	giv[62]	_	_
10-14	1252-1255	and	_	_	_	_
10-15	1256-1268	subsequently	_	_	_	_
10-16	1269-1276	present	_	_	_	_
10-17	1277-1280	the	abstract[63]	new[63]	_	_
10-18	1281-1290	antigenic	abstract[63]	new[63]	_	_
10-19	1291-1299	epitopes	abstract[63]	new[63]	_	_
10-20	1300-1302	on	_	_	_	_
10-21	1303-1308	major	place[65]|object[67]	new[65]|new[67]	_	_
10-22	1309-1327	histocompatibility	abstract|place[65]|object[67]	new|new[65]|new[67]	_	_
10-23	1328-1335	complex	place[65]|object[67]	new[65]|new[67]	_	_
10-24	1336-1337	(	object[67]	new[67]	_	_
10-25	1338-1341	MHC	abstract|object[67]	new|new[67]	_	_
10-26	1342-1343	)	object[67]	new[67]	_	_
10-27	1344-1353	molecules	object[67]	new[67]	_	_
10-28	1354-1355	.	_	_	_	_

#Text=At the same time , DCs up-regulate the maturation receptor , release potent cytokines , and migrate into lymph nodes to induce systemic immune responses .
11-1	1356-1358	At	_	_	_	_
11-2	1359-1362	the	time[68]	new[68]	_	_
11-3	1363-1367	same	time[68]	new[68]	_	_
11-4	1368-1372	time	time[68]	new[68]	_	_
11-5	1373-1374	,	_	_	_	_
11-6	1375-1378	DCs	place	giv	coref	12-9
11-7	1379-1390	up-regulate	_	_	_	_
11-8	1391-1394	the	abstract[71]	new[71]	_	_
11-9	1395-1405	maturation	time|abstract[71]	new|new[71]	coref	26-39
11-10	1406-1414	receptor	abstract[71]	new[71]	_	_
11-11	1415-1416	,	_	_	_	_
11-12	1417-1424	release	_	_	_	_
11-13	1425-1431	potent	abstract[72]	giv[72]	_	_
11-14	1432-1441	cytokines	abstract[72]	giv[72]	_	_
11-15	1442-1443	,	_	_	_	_
11-16	1444-1447	and	_	_	_	_
11-17	1448-1455	migrate	_	_	_	_
11-18	1456-1460	into	_	_	_	_
11-19	1461-1466	lymph	person|place[74]	new|new[74]	coref|coref	16-11|16-10[101_74]
11-20	1467-1472	nodes	place[74]	new[74]	_	_
11-21	1473-1475	to	_	_	_	_
11-22	1476-1482	induce	_	_	_	_
11-23	1483-1491	systemic	abstract[75]	giv[75]	coref	16-27[107_75]
11-24	1492-1498	immune	abstract[75]	giv[75]	_	_
11-25	1499-1508	responses	abstract[75]	giv[75]	_	_
11-26	1509-1510	.	_	_	_	_

#Text=The standard DC-based vaccine begins with first isolating DCs from the patient .
12-1	1511-1514	The	substance[76]	giv[76]	_	_
12-2	1515-1523	standard	substance[76]	giv[76]	_	_
12-3	1524-1532	DC-based	substance[76]	giv[76]	_	_
12-4	1533-1540	vaccine	substance[76]	giv[76]	_	_
12-5	1541-1547	begins	_	_	_	_
12-6	1548-1552	with	_	_	_	_
12-7	1553-1558	first	_	_	_	_
12-8	1559-1568	isolating	_	_	_	_
12-9	1569-1572	DCs	place	giv	coref	13-3
12-10	1573-1577	from	_	_	_	_
12-11	1578-1581	the	person[78]	new[78]	coref	13-8[80_78]
12-12	1582-1589	patient	person[78]	new[78]	_	_
12-13	1590-1591	.	_	_	_	_

#Text=Then , DCs are stimulated with the patient ’s tumor-associated antigen in vitro , and the antigen-stimulated DCs are injected directly back into the patient to induce the activation of T lymphocytes .
13-1	1592-1596	Then	_	_	_	_
13-2	1597-1598	,	_	_	_	_
13-3	1599-1602	DCs	place	giv	coref	13-16[83_0]
13-4	1603-1606	are	_	_	_	_
13-5	1607-1617	stimulated	_	_	_	_
13-6	1618-1622	with	_	_	_	_
13-7	1623-1626	the	substance[81]	giv[81]	_	_
13-8	1627-1634	patient	person[80]|substance[81]	giv[80]|giv[81]	coref	13-24[84_80]
13-9	1635-1637	’s	person[80]|substance[81]	giv[80]|giv[81]	_	_
13-10	1638-1654	tumor-associated	substance[81]	giv[81]	_	_
13-11	1655-1662	antigen	substance[81]	giv[81]	_	_
13-12	1663-1665	in	_	_	_	_
13-13	1666-1671	vitro	organization	new	coref	17-4[108_0]
13-14	1672-1673	,	_	_	_	_
13-15	1674-1677	and	_	_	_	_
13-16	1678-1681	the	place[83]	giv[83]	coref	16-3[99_83]
13-17	1682-1700	antigen-stimulated	place[83]	giv[83]	_	_
13-18	1701-1704	DCs	place[83]	giv[83]	_	_
13-19	1705-1708	are	_	_	_	_
13-20	1709-1717	injected	_	_	_	_
13-21	1718-1726	directly	_	_	_	_
13-22	1727-1731	back	_	_	_	_
13-23	1732-1736	into	_	_	_	_
13-24	1737-1740	the	person[84]	giv[84]	coref	14-2[88_84]
13-25	1741-1748	patient	person[84]	giv[84]	_	_
13-26	1749-1751	to	_	_	_	_
13-27	1752-1758	induce	_	_	_	_
13-28	1759-1762	the	event[85]	new[85]	_	_
13-29	1763-1773	activation	event[85]	new[85]	_	_
13-30	1774-1776	of	event[85]	new[85]	_	_
13-31	1777-1778	T	event[85]|person|substance[87]	new[85]|giv|giv[87]	coref|coref	16-16|16-16[103_87]
13-32	1779-1790	lymphocytes	event[85]|substance[87]	new[85]|giv[87]	_	_
13-33	1791-1792	.	_	_	_	_

#Text=The patient ’s immune system will generate the tumor-specific immune response to destroy cancer cells and prevent cancer recurrence .
14-1	1793-1796	The	abstract[89]	new[89]	coref	18-8[116_89]
14-2	1797-1804	patient	person[88]|abstract[89]	giv[88]|new[89]	_	_
14-3	1805-1807	’s	person[88]|abstract[89]	giv[88]|new[89]	_	_
14-4	1808-1814	immune	abstract[89]	new[89]	_	_
14-5	1815-1821	system	abstract[89]	new[89]	_	_
14-6	1822-1826	will	_	_	_	_
14-7	1827-1835	generate	_	_	_	_
14-8	1836-1839	the	abstract[90]	new[90]	coref	17-17[112_90]
14-9	1840-1854	tumor-specific	abstract[90]	new[90]	_	_
14-10	1855-1861	immune	abstract[90]	new[90]	_	_
14-11	1862-1870	response	abstract[90]	new[90]	_	_
14-12	1871-1873	to	_	_	_	_
14-13	1874-1881	destroy	_	_	_	_
14-14	1882-1888	cancer	abstract|place[92]	giv|giv[92]	coref|coref	14-18|24-16[172_92]
14-15	1889-1894	cells	place[92]	giv[92]	_	_
14-16	1895-1898	and	_	_	_	_
14-17	1899-1906	prevent	_	_	_	_
14-18	1907-1913	cancer	abstract|event[94]	giv|new[94]	coref	20-10
14-19	1914-1924	recurrence	event[94]	new[94]	_	_
14-20	1925-1926	.	_	_	_	_

#Text=However , several drawbacks restrict the clinical efficacy of DC therapy .
15-1	1927-1934	However	_	_	_	_
15-2	1935-1936	,	_	_	_	_
15-3	1937-1944	several	abstract[95]	new[95]	_	_
15-4	1945-1954	drawbacks	abstract[95]	new[95]	_	_
15-5	1955-1963	restrict	_	_	_	_
15-6	1964-1967	the	abstract[96]	new[96]	_	_
15-7	1968-1976	clinical	abstract[96]	new[96]	_	_
15-8	1977-1985	efficacy	abstract[96]	new[96]	_	_
15-9	1986-1988	of	abstract[96]	new[96]	_	_
15-10	1989-1991	DC	abstract[96]|person|abstract[98]	new[96]|new|giv[98]	coref	26-36
15-11	1992-1999	therapy	abstract[96]|abstract[98]	new[96]|giv[98]	_	_
15-12	2000-2001	.	_	_	_	_

#Text=First , only a few DCs actually migrate to the lymph nodes and interact with T lymphocytes , with the result of a failure to induce antitumor immune responses .
16-1	2002-2007	First	_	_	_	_
16-2	2008-2009	,	_	_	_	_
16-3	2010-2014	only	place[99]	giv[99]	coref	17-9[110_99]
16-4	2015-2016	a	place[99]	giv[99]	_	_
16-5	2017-2020	few	place[99]	giv[99]	_	_
16-6	2021-2024	DCs	place[99]	giv[99]	_	_
16-7	2025-2033	actually	_	_	_	_
16-8	2034-2041	migrate	_	_	_	_
16-9	2042-2044	to	_	_	_	_
16-10	2045-2048	the	place[101]	giv[101]	coref	19-1[123_101]
16-11	2049-2054	lymph	person|place[101]	giv|giv[101]	coref	19-2
16-12	2055-2060	nodes	place[101]	giv[101]	_	_
16-13	2061-2064	and	_	_	_	_
16-14	2065-2073	interact	_	_	_	_
16-15	2074-2078	with	_	_	_	_
16-16	2079-2080	T	person|substance[103]	giv|giv[103]	_	_
16-17	2081-2092	lymphocytes	substance[103]	giv[103]	_	_
16-18	2093-2094	,	_	_	_	_
16-19	2095-2099	with	_	_	_	_
16-20	2100-2103	the	abstract[104]	new[104]	_	_
16-21	2104-2110	result	abstract[104]	new[104]	_	_
16-22	2111-2113	of	abstract[104]	new[104]	_	_
16-23	2114-2115	a	abstract[104]|event[105]	new[104]|new[105]	_	_
16-24	2116-2123	failure	abstract[104]|event[105]	new[104]|new[105]	_	_
16-25	2124-2126	to	abstract[104]|event[105]	new[104]|new[105]	_	_
16-26	2127-2133	induce	abstract[104]|event[105]	new[104]|new[105]	_	_
16-27	2134-2143	antitumor	abstract[104]|event[105]|abstract|abstract[107]	new[104]|new[105]|new|giv[107]	coref|coref	19-8[124_107]|25-35
16-28	2144-2150	immune	abstract[104]|event[105]|abstract[107]	new[104]|new[105]|giv[107]	_	_
16-29	2151-2160	responses	abstract[104]|event[105]|abstract[107]	new[104]|new[105]|giv[107]	_	_
16-30	2161-2162	.	_	_	_	_

#Text=Moreover , the in vitro culture cannot generate sufficiently powerful DCs , with the result of a weak immune response and limited therapeutic benefit .
17-1	2163-2171	Moreover	_	_	_	_
17-2	2172-2173	,	_	_	_	_
17-3	2174-2177	the	abstract[109]	new[109]	_	_
17-4	2178-2180	in	organization[108]|abstract[109]	giv[108]|new[109]	coref	26-41[0_108]
17-5	2181-2186	vitro	organization[108]|abstract[109]	giv[108]|new[109]	_	_
17-6	2187-2194	culture	abstract[109]	new[109]	_	_
17-7	2195-2201	cannot	_	_	_	_
17-8	2202-2210	generate	_	_	_	_
17-9	2211-2223	sufficiently	place[110]	giv[110]	_	_
17-10	2224-2232	powerful	place[110]	giv[110]	_	_
17-11	2233-2236	DCs	place[110]	giv[110]	_	_
17-12	2237-2238	,	_	_	_	_
17-13	2239-2243	with	_	_	_	_
17-14	2244-2247	the	abstract[111]	new[111]	_	_
17-15	2248-2254	result	abstract[111]	new[111]	_	_
17-16	2255-2257	of	abstract[111]	new[111]	_	_
17-17	2258-2259	a	abstract[111]|abstract[112]	new[111]|giv[112]	coref	18-25[120_112]
17-18	2260-2264	weak	abstract[111]|abstract[112]	new[111]|giv[112]	_	_
17-19	2265-2271	immune	abstract[111]|abstract[112]	new[111]|giv[112]	_	_
17-20	2272-2280	response	abstract[111]|abstract[112]	new[111]|giv[112]	_	_
17-21	2281-2284	and	abstract[111]	new[111]	_	_
17-22	2285-2292	limited	abstract[111]|abstract[113]	new[111]|new[113]	ana	18-3[0_113]
17-23	2293-2304	therapeutic	abstract[111]|abstract[113]	new[111]|new[113]	_	_
17-24	2305-2312	benefit	abstract[111]|abstract[113]	new[111]|new[113]	_	_
17-25	2313-2314	.	_	_	_	_

#Text=Thus , it is important to establish an in vitro culturing system or an in vivo DC delivery system that can more reliably induce the immune response and more potently deliver antitumor immunity .
18-1	2315-2319	Thus	_	_	_	_
18-2	2320-2321	,	_	_	_	_
18-3	2322-2324	it	abstract	giv	_	_
18-4	2325-2327	is	_	_	_	_
18-5	2328-2337	important	_	_	_	_
18-6	2338-2340	to	_	_	_	_
18-7	2341-2350	establish	_	_	_	_
18-8	2351-2353	an	abstract[116]	giv[116]	coref	18-14[119_116]
18-9	2354-2356	in	abstract[116]	giv[116]	_	_
18-10	2357-2362	vitro	abstract[116]	giv[116]	_	_
18-11	2363-2372	culturing	time|abstract[116]	new|giv[116]	_	_
18-12	2373-2379	system	abstract[116]	giv[116]	_	_
18-13	2380-2382	or	_	_	_	_
18-14	2383-2385	an	abstract[119]	giv[119]	_	_
18-15	2386-2388	in	abstract[119]	giv[119]	_	_
18-16	2389-2393	vivo	abstract[119]	giv[119]	_	_
18-17	2394-2396	DC	place|abstract[118]|abstract[119]	new|new[118]|giv[119]	_	_
18-18	2397-2405	delivery	abstract[118]|abstract[119]	new[118]|giv[119]	_	_
18-19	2406-2412	system	abstract[119]	giv[119]	_	_
18-20	2413-2417	that	abstract[119]	giv[119]	_	_
18-21	2418-2421	can	abstract[119]	giv[119]	_	_
18-22	2422-2426	more	abstract[119]	giv[119]	_	_
18-23	2427-2435	reliably	abstract[119]	giv[119]	_	_
18-24	2436-2442	induce	abstract[119]	giv[119]	_	_
18-25	2443-2446	the	abstract[119]|abstract[120]	giv[119]|giv[120]	coref	19-39[135_120]
18-26	2447-2453	immune	abstract[119]|abstract[120]	giv[119]|giv[120]	_	_
18-27	2454-2462	response	abstract[119]|abstract[120]	giv[119]|giv[120]	_	_
18-28	2463-2466	and	abstract[119]	giv[119]	_	_
18-29	2467-2471	more	abstract[119]	giv[119]	_	_
18-30	2472-2480	potently	abstract[119]	giv[119]	_	_
18-31	2481-2488	deliver	abstract[119]	giv[119]	_	_
18-32	2489-2498	antitumor	abstract[119]|abstract[121]	giv[119]|giv[121]	coref	25-31[183_121]
18-33	2499-2507	immunity	abstract[119]|abstract[121]	giv[119]|giv[121]	_	_
18-34	2508-2509	.	_	_	_	_

#Text=The lymph nodes are extremely critical in responses to pathogens or danger signals , and their major functions are to filter out deleterious substances by their unique mesh microstructure , to maintain matured immunocytes , and to initiate the antigen-specific adaptive immune response .
19-1	2510-2513	The	place[123]	giv[123]	ana	19-16[0_123]
19-2	2514-2519	lymph	person|place[123]	giv|giv[123]	coref	20-2
19-3	2520-2525	nodes	place[123]	giv[123]	_	_
19-4	2526-2529	are	_	_	_	_
19-5	2530-2539	extremely	_	_	_	_
19-6	2540-2548	critical	_	_	_	_
19-7	2549-2551	in	_	_	_	_
19-8	2552-2561	responses	abstract[124]	giv[124]	_	_
19-9	2562-2564	to	abstract[124]	giv[124]	_	_
19-10	2565-2574	pathogens	abstract[124]|substance	giv[124]|new	_	_
19-11	2575-2577	or	abstract[124]	giv[124]	_	_
19-12	2578-2584	danger	abstract[124]|abstract|abstract[127]	giv[124]|new|new[127]	_	_
19-13	2585-2592	signals	abstract[124]|abstract[127]	giv[124]|new[127]	_	_
19-14	2593-2594	,	_	_	_	_
19-15	2595-2598	and	_	_	_	_
19-16	2599-2604	their	place|abstract[129]	giv|new[129]	ana	19-26
19-17	2605-2610	major	abstract[129]	new[129]	_	_
19-18	2611-2620	functions	abstract[129]	new[129]	_	_
19-19	2621-2624	are	_	_	_	_
19-20	2625-2627	to	_	_	_	_
19-21	2628-2634	filter	_	_	_	_
19-22	2635-2638	out	_	_	_	_
19-23	2639-2650	deleterious	substance[130]	giv[130]	_	_
19-24	2651-2661	substances	substance[130]	giv[130]	_	_
19-25	2662-2664	by	_	_	_	_
19-26	2665-2670	their	place|abstract[133]	giv|new[133]	coref|coref	20-1[137_0]|26-20[192_133]
19-27	2671-2677	unique	abstract[133]	new[133]	_	_
19-28	2678-2682	mesh	object|abstract[133]	new|new[133]	_	_
19-29	2683-2697	microstructure	abstract[133]	new[133]	_	_
19-30	2698-2699	,	_	_	_	_
19-31	2700-2702	to	_	_	_	_
19-32	2703-2711	maintain	_	_	_	_
19-33	2712-2719	matured	abstract[134]	new[134]	_	_
19-34	2720-2731	immunocytes	abstract[134]	new[134]	_	_
19-35	2732-2733	,	_	_	_	_
19-36	2734-2737	and	_	_	_	_
19-37	2738-2740	to	_	_	_	_
19-38	2741-2749	initiate	_	_	_	_
19-39	2750-2753	the	abstract[135]	giv[135]	coref	25-34[185_135]
19-40	2754-2770	antigen-specific	abstract[135]	giv[135]	_	_
19-41	2771-2779	adaptive	abstract[135]	giv[135]	_	_
19-42	2780-2786	immune	abstract[135]	giv[135]	_	_
19-43	2787-2795	response	abstract[135]	giv[135]	_	_
19-44	2796-2797	.	_	_	_	_

#Text=The lymph nodes might lose their function because of cancer , obstruction , or infection ; in such cases , surgical resection of lymph nodes is usually indicated .
20-1	2798-2801	The	place[137]	giv[137]	ana	20-6[0_137]
20-2	2802-2807	lymph	person|place[137]	giv|giv[137]	coref	20-24
20-3	2808-2813	nodes	place[137]	giv[137]	_	_
20-4	2814-2819	might	_	_	_	_
20-5	2820-2824	lose	_	_	_	_
20-6	2825-2830	their	place|abstract[139]	giv|new[139]	coref|coref	20-24[146_0]|24-19[173_139]
20-7	2831-2839	function	abstract[139]	new[139]	_	_
20-8	2840-2847	because	_	_	_	_
20-9	2848-2850	of	_	_	_	_
20-10	2851-2857	cancer	abstract	giv	coref	21-20
20-11	2858-2859	,	_	_	_	_
20-12	2860-2871	obstruction	object	new	_	_
20-13	2872-2873	,	_	_	_	_
20-14	2874-2876	or	_	_	_	_
20-15	2877-2886	infection	event	new	coref	21-16[152_0]
20-16	2887-2888	;	_	_	_	_
20-17	2889-2891	in	_	_	_	_
20-18	2892-2896	such	event[143]	new[143]	_	_
20-19	2897-2902	cases	event[143]	new[143]	_	_
20-20	2903-2904	,	_	_	_	_
20-21	2905-2913	surgical	event[144]	new[144]	coref	21-3[149_144]
20-22	2914-2923	resection	event[144]	new[144]	_	_
20-23	2924-2926	of	event[144]	new[144]	_	_
20-24	2927-2932	lymph	event[144]|person|place[146]	new[144]|giv|giv[146]	coref	21-3
20-25	2933-2938	nodes	event[144]|place[146]	new[144]|giv[146]	_	_
20-26	2939-2941	is	_	_	_	_
20-27	2942-2949	usually	_	_	_	_
20-28	2950-2959	indicated	_	_	_	_
20-29	2960-2961	.	_	_	_	_

#Text=However , lymph node resection often causes a wide range of other problems such as increased infection , impaired cancer surveillance , and lymphedema .
21-1	2962-2969	However	_	_	_	_
21-2	2970-2971	,	_	_	_	_
21-3	2972-2977	lymph	person|object[148]|event[149]	giv|new[148]|giv[149]	coref|coref	22-8|22-9[0_148]
21-4	2978-2982	node	object[148]|event[149]	new[148]|giv[149]	_	_
21-5	2983-2992	resection	event[149]	giv[149]	_	_
21-6	2993-2998	often	_	_	_	_
21-7	2999-3005	causes	_	_	_	_
21-8	3006-3007	a	abstract[150]	new[150]	_	_
21-9	3008-3012	wide	abstract[150]	new[150]	_	_
21-10	3013-3018	range	abstract[150]	new[150]	_	_
21-11	3019-3021	of	abstract[150]	new[150]	_	_
21-12	3022-3027	other	abstract[150]|abstract[151]	new[150]|new[151]	_	_
21-13	3028-3036	problems	abstract[150]|abstract[151]	new[150]|new[151]	_	_
21-14	3037-3041	such	abstract[150]|abstract[151]	new[150]|new[151]	_	_
21-15	3042-3044	as	abstract[150]|abstract[151]	new[150]|new[151]	_	_
21-16	3045-3054	increased	abstract[150]|abstract[151]|event[152]	new[150]|new[151]|giv[152]	_	_
21-17	3055-3064	infection	abstract[150]|abstract[151]|event[152]	new[150]|new[151]|giv[152]	_	_
21-18	3065-3066	,	abstract[150]|abstract[151]	new[150]|new[151]	_	_
21-19	3067-3075	impaired	abstract[150]|abstract[151]|abstract[154]	new[150]|new[151]|new[154]	_	_
21-20	3076-3082	cancer	abstract[150]|abstract[151]|abstract|abstract[154]	new[150]|new[151]|giv|new[154]	_	_
21-21	3083-3095	surveillance	abstract[150]|abstract[151]|abstract[154]	new[150]|new[151]|new[154]	_	_
21-22	3096-3097	,	abstract[150]|abstract[151]	new[150]|new[151]	_	_
21-23	3098-3101	and	abstract[150]|abstract[151]	new[150]|new[151]	_	_
21-24	3102-3112	lymphedema	abstract[150]|abstract[151]|abstract	new[150]|new[151]|new	_	_
21-25	3113-3114	.	_	_	_	_

#Text=Consequently , a promising technique for functional lymph node restoration is urgently needed .
22-1	3115-3127	Consequently	_	_	_	_
22-2	3128-3129	,	_	_	_	_
22-3	3130-3131	a	abstract[156]	new[156]	_	_
22-4	3132-3141	promising	abstract[156]	new[156]	_	_
22-5	3142-3151	technique	abstract[156]	new[156]	_	_
22-6	3152-3155	for	abstract[156]	new[156]	_	_
22-7	3156-3166	functional	abstract[156]|event[159]	new[156]|new[159]	_	_
22-8	3167-3172	lymph	abstract[156]|person|event[159]	new[156]|giv|new[159]	coref	24-9
22-9	3173-3177	node	abstract[156]|object|event[159]	new[156]|giv|new[159]	coref	24-10
22-10	3178-3189	restoration	abstract[156]|event[159]	new[156]|new[159]	_	_
22-11	3190-3192	is	_	_	_	_
22-12	3193-3201	urgently	_	_	_	_
22-13	3202-3208	needed	_	_	_	_
22-14	3209-3210	.	_	_	_	_

#Text=Decellularization has emerged as a process for producing a natural extracellular matrix ( ECM ) , which preserves the intrinsic biological cues and architectural structure of the original tissue .
23-1	3211-3228	Decellularization	abstract	new	_	_
23-2	3229-3232	has	_	_	_	_
23-3	3233-3240	emerged	_	_	_	_
23-4	3241-3243	as	_	_	_	_
23-5	3244-3245	a	abstract[161]	new[161]	_	_
23-6	3246-3253	process	abstract[161]	new[161]	_	_
23-7	3254-3257	for	abstract[161]	new[161]	_	_
23-8	3258-3267	producing	abstract[161]	new[161]	_	_
23-9	3268-3269	a	abstract[161]|substance[162]	new[161]|new[162]	_	_
23-10	3270-3277	natural	abstract[161]|substance[162]	new[161]|new[162]	_	_
23-11	3278-3291	extracellular	abstract[161]|substance[162]	new[161]|new[162]	_	_
23-12	3292-3298	matrix	abstract[161]|substance[162]	new[161]|new[162]	_	_
23-13	3299-3300	(	_	_	_	_
23-14	3301-3304	ECM	abstract	new	coref	25-5[175_0]
23-15	3305-3306	)	_	_	_	_
23-16	3307-3308	,	_	_	_	_
23-17	3309-3314	which	_	_	_	_
23-18	3315-3324	preserves	_	_	_	_
23-19	3325-3328	the	abstract[164]	new[164]	_	_
23-20	3329-3338	intrinsic	abstract[164]	new[164]	_	_
23-21	3339-3349	biological	abstract[164]	new[164]	_	_
23-22	3350-3354	cues	abstract[164]	new[164]	_	_
23-23	3355-3358	and	_	_	_	_
23-24	3359-3372	architectural	abstract[165]	new[165]	_	_
23-25	3373-3382	structure	abstract[165]	new[165]	_	_
23-26	3383-3385	of	abstract[165]	new[165]	_	_
23-27	3386-3389	the	abstract[165]|object[166]	new[165]|new[166]	ana	24-1[0_166]
23-28	3390-3398	original	abstract[165]|object[166]	new[165]|new[166]	_	_
23-29	3399-3405	tissue	abstract[165]|object[166]	new[165]|new[166]	_	_
23-30	3406-3407	.	_	_	_	_

#Text=It provides a strategy by which to fabricate lymph node scaffolds on which to grow immune cells with immunological function .
24-1	3408-3410	It	object	giv	_	_
24-2	3411-3419	provides	_	_	_	_
24-3	3420-3421	a	abstract[168]	new[168]	_	_
24-4	3422-3430	strategy	abstract[168]	new[168]	_	_
24-5	3431-3433	by	abstract[168]	new[168]	_	_
24-6	3434-3439	which	abstract[168]	new[168]	_	_
24-7	3440-3442	to	abstract[168]	new[168]	_	_
24-8	3443-3452	fabricate	abstract[168]	new[168]	_	_
24-9	3453-3458	lymph	abstract[168]|person|object[171]	new[168]|giv|new[171]	coref|coref	25-22[181_171]|26-12
24-10	3459-3463	node	abstract[168]|object|object[171]	new[168]|giv|new[171]	coref	26-12[189_0]
24-11	3464-3473	scaffolds	abstract[168]|object[171]	new[168]|new[171]	_	_
24-12	3474-3476	on	_	_	_	_
24-13	3477-3482	which	_	_	_	_
24-14	3483-3485	to	_	_	_	_
24-15	3486-3490	grow	_	_	_	_
24-16	3491-3497	immune	place[172]	giv[172]	coref	25-15[179_172]
24-17	3498-3503	cells	place[172]	giv[172]	_	_
24-18	3504-3508	with	place[172]	giv[172]	_	_
24-19	3509-3522	immunological	place[172]|abstract[173]	giv[172]|giv[173]	_	_
24-20	3523-3531	function	place[172]|abstract[173]	giv[172]|giv[173]	_	_
24-21	3532-3533	.	_	_	_	_

#Text=Previous studies demonstrated that spleen-derived decellularized ECM or lymph node-associated decellularized ECM can deliver immune cells and promote the organization of lymphoid-like scaffolds ; however , whether these can induce antigen-specific immunity or the antitumor immune response is still unknown .
25-1	3534-3542	Previous	abstract[174]	new[174]	_	_
25-2	3543-3550	studies	abstract[174]	new[174]	_	_
25-3	3551-3563	demonstrated	_	_	_	_
25-4	3564-3568	that	_	_	_	_
25-5	3569-3583	spleen-derived	abstract[175]|abstract[176]	giv[175]|new[176]	coref|ana	25-9[178_175]|25-28[0_176]
25-6	3584-3598	decellularized	abstract[175]|abstract[176]	giv[175]|new[176]	_	_
25-7	3599-3602	ECM	abstract[175]|abstract[176]	giv[175]|new[176]	_	_
25-8	3603-3605	or	abstract[176]	new[176]	_	_
25-9	3606-3611	lymph	abstract[176]|abstract[178]	new[176]|giv[178]	coref	26-24[0_178]
25-10	3612-3627	node-associated	abstract[176]|abstract|abstract[178]	new[176]|new|giv[178]	_	_
25-11	3628-3642	decellularized	abstract[176]|abstract[178]	new[176]|giv[178]	_	_
25-12	3643-3646	ECM	abstract[176]|abstract[178]	new[176]|giv[178]	_	_
25-13	3647-3650	can	_	_	_	_
25-14	3651-3658	deliver	_	_	_	_
25-15	3659-3665	immune	place[179]	giv[179]	_	_
25-16	3666-3671	cells	place[179]	giv[179]	_	_
25-17	3672-3675	and	_	_	_	_
25-18	3676-3683	promote	_	_	_	_
25-19	3684-3687	the	abstract[180]	new[180]	_	_
25-20	3688-3700	organization	abstract[180]	new[180]	_	_
25-21	3701-3703	of	abstract[180]	new[180]	_	_
25-22	3704-3717	lymphoid-like	abstract[180]|object[181]	new[180]|giv[181]	_	_
25-23	3718-3727	scaffolds	abstract[180]|object[181]	new[180]|giv[181]	_	_
25-24	3728-3729	;	_	_	_	_
25-25	3730-3737	however	_	_	_	_
25-26	3738-3739	,	_	_	_	_
25-27	3740-3747	whether	_	_	_	_
25-28	3748-3753	these	abstract	giv	_	_
25-29	3754-3757	can	_	_	_	_
25-30	3758-3764	induce	_	_	_	_
25-31	3765-3781	antigen-specific	abstract[183]	giv[183]	_	_
25-32	3782-3790	immunity	abstract[183]	giv[183]	_	_
25-33	3791-3793	or	_	_	_	_
25-34	3794-3797	the	abstract[185]	giv[185]	coref	27-17[206_185]
25-35	3798-3807	antitumor	abstract|abstract[185]	giv|giv[185]	coref	27-19
25-36	3808-3814	immune	abstract[185]	giv[185]	_	_
25-37	3815-3823	response	abstract[185]	giv[185]	_	_
25-38	3824-3826	is	_	_	_	_
25-39	3827-3832	still	_	_	_	_
25-40	3833-3840	unknown	_	_	_	_
25-41	3841-3842	.	_	_	_	_

#Text=The aim of this study was to establish a natural decellularized lymph node scaffold ( dLN ) , with preserved original microstructure and ECM , and to validate the ability of the dLN to support DC proliferation and maturation in vitro .
26-1	3843-3846	The	abstract[186]	new[186]	_	_
26-2	3847-3850	aim	abstract[186]	new[186]	_	_
26-3	3851-3853	of	abstract[186]	new[186]	_	_
26-4	3854-3858	this	abstract[186]|abstract[187]	new[186]|new[187]	coref	27-1[200_187]
26-5	3859-3864	study	abstract[186]|abstract[187]	new[186]|new[187]	_	_
26-6	3865-3868	was	_	_	_	_
26-7	3869-3871	to	_	_	_	_
26-8	3872-3881	establish	_	_	_	_
26-9	3882-3883	a	object[190]	new[190]	_	_
26-10	3884-3891	natural	object[190]	new[190]	_	_
26-11	3892-3906	decellularized	object[190]	new[190]	_	_
26-12	3907-3912	lymph	person|object[189]|object[190]	giv|giv[189]|new[190]	_	_
26-13	3913-3917	node	object[189]|object[190]	giv[189]|new[190]	_	_
26-14	3918-3926	scaffold	object[190]	new[190]	_	_
26-15	3927-3928	(	_	_	_	_
26-16	3929-3932	dLN	abstract	new	coref	26-32[195_0]
26-17	3933-3934	)	_	_	_	_
26-18	3935-3936	,	_	_	_	_
26-19	3937-3941	with	_	_	_	_
26-20	3942-3951	preserved	abstract[192]	giv[192]	_	_
26-21	3952-3960	original	abstract[192]	giv[192]	_	_
26-22	3961-3975	microstructure	abstract[192]	giv[192]	_	_
26-23	3976-3979	and	_	_	_	_
26-24	3980-3983	ECM	abstract	giv	_	_
26-25	3984-3985	,	_	_	_	_
26-26	3986-3989	and	_	_	_	_
26-27	3990-3992	to	_	_	_	_
26-28	3993-4001	validate	_	_	_	_
26-29	4002-4005	the	abstract[194]	new[194]	_	_
26-30	4006-4013	ability	abstract[194]	new[194]	_	_
26-31	4014-4016	of	abstract[194]	new[194]	_	_
26-32	4017-4020	the	abstract[194]|abstract[195]	new[194]|giv[195]	_	_
26-33	4021-4024	dLN	abstract[194]|abstract[195]	new[194]|giv[195]	_	_
26-34	4025-4027	to	abstract[194]|abstract[195]	new[194]|giv[195]	_	_
26-35	4028-4035	support	abstract[194]|abstract[195]	new[194]|giv[195]	_	_
26-36	4036-4038	DC	abstract[194]|abstract[195]|person|event[197]	new[194]|giv[195]|giv|new[197]	_	_
26-37	4039-4052	proliferation	abstract[194]|abstract[195]|event[197]	new[194]|giv[195]|new[197]	_	_
26-38	4053-4056	and	abstract[194]|abstract[195]	new[194]|giv[195]	_	_
26-39	4057-4067	maturation	abstract[194]|abstract[195]|time	new[194]|giv[195]|giv	_	_
26-40	4068-4070	in	abstract[194]|abstract[195]	new[194]|giv[195]	_	_
26-41	4071-4076	vitro	abstract[194]|abstract[195]|organization	new[194]|giv[195]|giv	_	_
26-42	4077-4078	.	_	_	_	_

#Text=The study also aimed to verify whether a bone marrow dendritic cell ( BMDC)-dLN can activate a specific antitumor immune response in vivo .
27-1	4079-4082	The	abstract[200]	giv[200]	_	_
27-2	4083-4088	study	abstract[200]	giv[200]	_	_
27-3	4089-4093	also	_	_	_	_
27-4	4094-4099	aimed	_	_	_	_
27-5	4100-4102	to	_	_	_	_
27-6	4103-4109	verify	_	_	_	_
27-7	4110-4117	whether	_	_	_	_
27-8	4118-4119	a	object[203]	giv[203]	_	_
27-9	4120-4124	bone	object|animal[202]|object[203]	new|new[202]|giv[203]	_	_
27-10	4125-4131	marrow	animal[202]|object[203]	new[202]|giv[203]	_	_
27-11	4132-4141	dendritic	object[203]	giv[203]	_	_
27-12	4142-4146	cell	object[203]	giv[203]	_	_
27-13	4147-4148	(	_	_	_	_
27-14	4149-4158	BMDC)-dLN	abstract	new	_	_
27-15	4159-4162	can	_	_	_	_
27-16	4163-4171	activate	_	_	_	_
27-17	4172-4173	a	abstract[206]	giv[206]	_	_
27-18	4174-4182	specific	abstract[206]	giv[206]	_	_
27-19	4183-4192	antitumor	abstract|abstract[206]	giv|giv[206]	_	_
27-20	4193-4199	immune	abstract[206]	giv[206]	_	_
27-21	4200-4208	response	abstract[206]	giv[206]	_	_
27-22	4209-4211	in	_	_	_	_
27-23	4212-4216	vivo	abstract	new	_	_
27-24	4217-4218	.	_	_	_	_
